ArticleAnnals of hematology2026
Comprehensive geriatric assessment (CGA) scale does not effectively identify elderly AML patients suitable for intensive induction chemotherapy - a multicenter study from Polish Adult Leukemia Group.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standard scales, such as ECOG Performance Status, Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), and Activities of Daily Living (ADL), are commonly used to stratify patients with acute myeloid leukemia (AML) for intensive chemotherapy (IC). Comprehensive geriatric assessment (CGA) may further identify patients at risk of treatment-related toxicity, but it is underutilized due to time constraints. We aimed to evaluate the predictive relevance of CGA domains in elderly AML patients selected for IC using ECOG, HCT-CI, and ADL. In this prospective study, patients aged 60–75 were eligible for IC if they had ECOG < 2, HCT-CI < 3, and ADL = 6. Regimens included daunorubicin and cytarabine (DA) with or without cladribine (DAC). Additional CGA domains assessed were: Instrumental Activities of Daily Living (IADL), Timed Up-and-Go Test (TUG), Geriatric Depression Scale (GDS), Mini-Mental State Examination (MMSE), and Mini Nutritional Assessment (MNA), screening tests Geriatric 8 (G8) and Vulnerable Elders Survey-13 (VES-13). Eighty-five patients (median age: 65) were analyzed. HCT-CI scores of 0–1 were seen in 72%; 23.5% had secondary AML. Intermediate and adverse cytogenetic risk was present in 33% and 38%, respectively. Complete remission with or without incomplete hematologic recovery (CR/CRi) was achieved in 65%. Median overall survival (OS) and relapse-free survival (RFS) were 16.0 and 15.3 months, respectively. No significant differences in CR, OS, or RFS existed between DA and DAC regimens. None of the tested CGA domains significantly affected CR/CRi, OS, or RFS. In conclusion, CGA domains did not provide additional predictive value in AML patients selected for IC based on ECOG < 2, HCT-CI < 3, and ADL = 6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.